Cells for immunotherapy engineered for targeting CD38 antigen and for CD38 gene inactivation
AssigneeCellectis
InventorMathilde Dusseaux
Life of this patent
Estimating the term…
Abstract
Methods of developing genetically engineered immune cells for immunotherapy, which can be endowed with Chimeric Antigen Receptors targeting an antigen marker that is common to both the pathological cells and said CD38 immune by the fact that the genes encoding said markers are inactivated in said immune cells by a rare cutting endonuclease such as TALEN, Cas9 or argonaute.
Claims15
An anti-CD38 specific chimeric antigen receptor (anti-CD38 CAR) comprising an extra cellular ligand binding-domain comprising VH and VL from a monoclonal anti-CD38 antibody, a hinge, a transmembrane domain, and a cytoplasmic domain comprising a CD3 zeta signaling domain and a co-stimulatory domain from 4-1BB,
- wherein said VH and VL comprise the CDRs sequences of respectively SEQ ID NO.15-17 and SEQ ID NO.11-13;
- respectively SEQ ID NO.63-65 and SEQ ID NO.59-61;
- respectively SEQ ID NO.55-57 and SEQ ID NO.51-53;
- respectively SEQ ID NO.31-33 and SEQ ID NO.27-29;
- respectively SEQ ID NO.39-41 and SEQ ID NO.35-37;
- respectively SEQ ID NO.47-49 and SEQ ID NO.43-45;
- respectively SEQ ID NO.23-25 and SEQ ID NO.19-21.
Dependencies are inferred from the claim text.